GDS Muscle and Articulation Chain Treatment for Chronic LBP and Spinal Stenosis (GDS)

August 24, 2021 updated by: Sidsel Lombardo, The Hospital of Vestfold

Evaluation of "Muscle and Articulation Chains GDS Method" Treatment for Inoperable Low Back Pain Patients - a Randomised, Controlled Pilot Trial.

Our purpose is to conduct a pilot study to evaluate GDS muscle and articulation chain treatment for inoperable spine patients with degenerative changes in the lumbar spine, compared to "standard treatment" (any other chosen treatment). The pilot study will be conducted as a randomized controlled trial (RCT) to investigate feasibility and benefit of GDS muscle and articulation chain treatment on pain, function and quality of life. The pilot study will form the basis for a later full-scale randomized study and the following research questions will be addressed:

  1. To what extent were the criteria for inclusion in the study suitable?
  2. How did the recruitment procedure work?
  3. How did the participants experience GDS treatment?
  4. To what extent were the selected outcome measures suitable at the different evaluation moments, and which outcome measure tested in this pilot study would be most suitable as primary outcome measure in a full-scale study? (user experience will be included in the evaluation)
  5. How was the change in the primary outcome measure (Oswestry Disability Index)?
  6. What will be the estimated time for inclusion of the required number of participants in a full-scale study? (required sample size will be based on strength calculation /saving of the outcome target chosen as primary outcome measure for full scale study) The study is a pilot study with a randomized controlled design, with follow-up after 3-4 months. Thirty patients are recruited and receive baseline examination and respond to the questionnaires before randomization. The patients receive a questionnaire by mail 3-4 months after inclusion (after the treatment is completed for intervention group ). The pilot study will be one-way blinded.

Study Overview

Detailed Description

Design: randomized, controlled trial with intervention and control arm. Recruitment: Patients are recruited from those relegated from GPs in Vestfold to the spine surgeons at Vestfold Hospital (SIV) for assessment of surgery. Participants who qualify for the study will be contacted by the project staff member (Sidsel Lombardo) who will provide the information about the study. Participants who are interested in participating will be assessed in terms of the study's inclusion and exclusion criteria. If these are met, the participant will be explained what the study is based on in detail, both orally and in writing (appendix in REK application). The participant is then asked if he / she is still willing to participate. They will then undergo the baseline survey, fill in the forms and then sign the consent declaration. Afterwards they are randomized to GDS treatment or standard therapy. Participants have the opportunity to quit along the way without affecting their health care and regular treatment.

Inclusion criteria

  • Women and men aged between 35 to 75 years, with chronic (> 3 months) low back pain, with or without irradiation in legs.
  • Degenerative changes in the lumbar spine verified on MR. Exclusion criteria
  • Severe psychiatric disorder
  • Comorbidity that prevents the patient from performing exercises and gradually increasing general activity when the back / leg function permits it.
  • Already had surgery with fixation of the lumbar spine.
  • Pregnancy
  • Being in process of assessing disability insurance or economic compensation for health reasons.

Randomization procedure: After baseline survey and answered questionnaire, participants will be randomized to intervention and control group using a data generated randomization sequence at a 1: 1 ratio. Statisticians at the Musculoskeletal Health Research Group (MUSKHealth.com) at OsloMet will assist with the randomization sequence.

Blinding: In this study, one cannot blind the participants nor the treating physiotherapist for which treatment they are receiving. However, research staff who collect and process data at the 3-4 month follow-up will be blinded to who is randomized to the intervention and control groups, respectively.

Intervention: The treatment group is examined and evaluated based on the principles of the "muscle and articulation chains GDS method", and receive until 8 treatments of one hour. They meet once a week in the beginning, more seldom towards the end of treatment. The participants pay for the individual treatments, but half prize of usual physiotherapy rate. The reason is that there is no extra money in SIV Hospital to provide free treatment, and that patients today pay regular rates for the same. Participants' follow-up to the intervention will be logged by the attending physiotherapist. The same applies to apostasy.

Control: The control group receives standard treatment from their GP, possibly referred to physiotherapy, chiropractor or the treatment option they prefer.

At baseline, imaging diagnostic findings regarding degenerative findings in the spine obtained from patient records will also be included. Data on function using Oswestry list f Data collection: Background variables such as age, gender, education level, marital status, mother tongue, height and weight will only be obtained at baseline (before randomization).

The same applies to mapping the risk of chronic back pain, which will be mapped using the STarT Back screening form [12].

Imaging diagnostic regarding degenerative findings in the spine obtained from patient records will also be included.

Functional data using the Oswestry list for functional limitations [10], pain using the VAS scale [8], health-related quality of life using the EQ-5D [11], risk for chronic back pain using the StarT Back screening form [12] and work ability will be obtained before and after intervention (3-4 months). A questionnaire at 3-4 months follow-up will be sent by mail, with a stamped envelope for return. Patients who do not respond will be reminded twice.

Statistical analysis and sample size: This pilot study will also be used to make a strength calculation for a full-scale RCT. Nevertheless, if we use minimum clinical important difference (MCID) estimates in primary outcome measures as a starting point for a strength calculation, we will get the following reasoning: MCID for ODI has been found to be between 8 and 10 points on the scale from 0 to 10 [10]. Assuming an expected difference between two groups of 8 ODI points with a standard deviation (SD) of 10 and significance level of 5%, then we will have 80% strength to detect this difference with a sample of 50 people in each group. We account for 15% drop-out, ie a full-scale study will require 115 patients. If the pilot study proves to be able to expect greater differences in ODI scores between the groups, then this number could be reduced, and vice versa. For this pilot study, the aim is to include totally 30 participants for intervention and control groups.

Study Type

Interventional

Enrollment (Actual)

30

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Larvik, Norway, 3257
        • Vestfold Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

35 years to 75 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Men and women, age 35-75 years, with cronic (>3 months) LBP, may have irradiation in legs.
  • Degenerative changes in the lumbar spine verified on MR.

Exclusion Criteria:

  • Severe psychiatric disorder.
  • Comorbidity that prevents the patient from performing exercises and gradually increasing general activity when the back /leg function gradually allows it.
  • Already had surgery with fixation of lumbar spine.
  • Being in process of assessing disability insurance or economic compenastion for Health reasons.
  • Pregnancy

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Muscle and Articulation chains GDS method treatment
Participants in the intervention Group are examined and treated according to the principles of "Muscle and Articulation Chains GDS Method". They receive GDS treatment individually, up to 8 sessions of 1 hour.
A physiotherapy method adapting treatment to patient's "terrain", or psychomorphology, using chosen techniques to balance tension between muscle chains, thus optimalizing posture and mouvement.
Other Names:
  • Les Chaines Musculaires et Articulaires Methode GDS
No Intervention: Control (treatment as usual)
The Control Group receives standard treatment from their RGP/ doctor. Some are prescribed physiotherapy or chiropractor treatment, or they choose their own alternatives.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Oswestry Disability Index
Time Frame: 4 months
Measures activity limitations
4 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Visual analogue scale (VAS)
Time Frame: 4 months
Measures pain on a line 0-100
4 months
EQ-5D-5L
Time Frame: 4 months
Health-related quality of life measurement tool
4 months
The Keele Start Back screening tool
Time Frame: 4 months
Psychosocial screening profile measurement tool
4 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Margreth Grotle, PhD, Oslo Metropolitan University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

November 14, 2018

Primary Completion (Actual)

October 3, 2020

Study Completion (Actual)

October 3, 2020

Study Registration Dates

First Submitted

June 2, 2020

First Submitted That Met QC Criteria

June 15, 2020

First Posted (Actual)

June 17, 2020

Study Record Updates

Last Update Posted (Actual)

August 30, 2021

Last Update Submitted That Met QC Criteria

August 24, 2021

Last Verified

August 1, 2021

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Low Back Pain, Recurrent

Clinical Trials on Muscle and articulation chains GDS method

Subscribe